Astellas Pharma Inc
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to m… Read more
Market Cap & Net Worth: Astellas Pharma Inc (ALPMF)
Astellas Pharma Inc (PINK:ALPMF) has a market capitalization of $16.93 Billion ($16.93 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #1137 globally and #878 in its home market, demonstrating a -5.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Astellas Pharma Inc's stock price $9.45 by its total outstanding shares 1791410514 (1.79 Billion).
Astellas Pharma Inc Market Cap History: 2015 to 2025
Astellas Pharma Inc's market capitalization history from 2015 to 2025. Data shows change from $19.21 Billion to $16.93 Billion (-0.91% CAGR).
Astellas Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Astellas Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Astellas Pharma Inc's market cap is 0.01 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.33x
Astellas Pharma Inc's market cap is 0.33 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $19.68 Billion | $1.37 Trillion | $193.69 Billion | 0.01x | 0.10x |
| 2017 | $17.71 Billion | $1.31 Trillion | $218.70 Billion | 0.01x | 0.08x |
| 2018 | $18.62 Billion | $1.30 Trillion | $164.68 Billion | 0.01x | 0.11x |
| 2019 | $25.21 Billion | $1.31 Trillion | $222.26 Billion | 0.02x | 0.11x |
| 2020 | $23.05 Billion | $1.30 Trillion | $195.41 Billion | 0.02x | 0.12x |
| 2021 | $24.78 Billion | $1.25 Trillion | $120.59 Billion | 0.02x | 0.21x |
| 2022 | $24.85 Billion | $1.30 Trillion | $124.09 Billion | 0.02x | 0.20x |
| 2023 | $20.14 Billion | $1.52 Trillion | $98.71 Billion | 0.01x | 0.20x |
| 2024 | $20.17 Billion | $1.60 Trillion | $17.05 Billion | 0.01x | 1.18x |
| 2025 | $16.93 Billion | $1.91 Trillion | $50.75 Billion | 0.01x | 0.33x |
Competitor Companies of ALPMF by Market Capitalization
Companies near Astellas Pharma Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Astellas Pharma Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Astellas Pharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Astellas Pharma Inc's market cap moved from $19.21 Billion to $ 16.93 Billion, with a yearly change of -0.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $16.93 Billion | -16.07% |
| 2024 | $20.17 Billion | +0.16% |
| 2023 | $20.14 Billion | -18.94% |
| 2022 | $24.85 Billion | +0.26% |
| 2021 | $24.78 Billion | +7.50% |
| 2020 | $23.05 Billion | -8.57% |
| 2019 | $25.21 Billion | +35.39% |
| 2018 | $18.62 Billion | +5.16% |
| 2017 | $17.71 Billion | -10.01% |
| 2016 | $19.68 Billion | +2.45% |
| 2015 | $19.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Astellas Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.93 Billion USD |
| MoneyControl | $16.93 Billion USD |
| MarketWatch | $16.93 Billion USD |
| marketcap.company | $16.93 Billion USD |
| Reuters | $16.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.